.

Make Better Decisions

  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Cipla
Cantor Fitzgerald
McKinsey
Covington
AstraZeneca
Queensland Health
Federal Trade Commission
Harvard Business School
Julphar
Dow

Generated: November 21, 2017

DrugPatentWatch Database Preview

VIAGRA Drug Profile

« Back to Dashboard

Which patents cover Viagra, and when can generic versions of Viagra launch?

Viagra is a drug marketed by Pfizer Inc and is included in one NDA. There is one patent protecting this drug and two Paragraph IV challenges.

This drug has forty-five patent family members in twenty-six countries and four supplementary protection certificates in four countries.

The generic ingredient in VIAGRA is sildenafil citrate. There are twenty drug master file entries for this compound. Thirty-six suppliers are listed for this compound. Additional details are available on the sildenafil citrate profile page.
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Pfizer Inc
VIAGRA
sildenafil citrate
TABLET;ORAL020895-001Mar 27, 1998RXYesNo► Subscribe► SubscribeY► Subscribe
Pfizer Inc
VIAGRA
sildenafil citrate
TABLET;ORAL020895-002Mar 27, 1998RXYesNo► Subscribe► SubscribeY► Subscribe
Pfizer Inc
VIAGRA
sildenafil citrate
TABLET;ORAL020895-003Mar 27, 1998RXYesYes► Subscribe► SubscribeY► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Tradename: VIAGRA

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Pfizer Inc
VIAGRA
sildenafil citrate
TABLET;ORAL020895-001Mar 27, 1998► Subscribe► Subscribe
Pfizer Inc
VIAGRA
sildenafil citrate
TABLET;ORAL020895-003Mar 27, 1998► Subscribe► Subscribe
Pfizer Inc
VIAGRA
sildenafil citrate
TABLET;ORAL020895-002Mar 27, 1998► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV (Patent) Challenges for VIAGRA

Drugname Dosage Strength RLD Submissiondate
sildenafil citrateTablets25 mg and 50 mgViagra11/19/2004
sildenafil citrateTablets100 mgViagra10/25/2004

International Patent Family for Tradename: VIAGRA

Country Document Number Estimated Expiration
Spain2113656► Subscribe
HungaryT73420► Subscribe
South Africa9404018► Subscribe
Norway954757► Subscribe
Russian Federation2373938► Subscribe
China1124926► Subscribe
Russian Federation2130776► Subscribe
Hungary227877► Subscribe
Taiwan292971► Subscribe
China1071118► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Tradename: VIAGRA

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
C/GB99/004United Kingdom► SubscribePRODUCT NAME: SILDENAFIL AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, IN PARTICULAR THE CITRATE SALT; REGISTERED: CH 54642 19980622; UK EU/1/98/077/001 19980914; UK EU/1/98/077/002 19980914; UK EU/1/98/077/003 19980914; UK EU/1/98/077/004 19980914; UK EU/1/98/077/005 19980914; UK EU/1/98/077/006 19980914; UK EU/1/98/077/007 19980914; UK EU/1/98/077/008 19980914; UK EU/1/98/077/009 19980914; UK EU/1/98/077/010 19980914; UK EU/1/98/077/011 19980914; UK EU/1/98/077/012 19980914
90005Netherlands► SubscribePRODUCT NAME: SILDENAFIL, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AAN- VAARDBAAR ZOUT, IN HET BIJZONDER SILDENAFIL CITRAAT; NATL REGISTRATION NO/DATE: EU/1/98/077/001-012 19980914; FIRST REGISTRATION: CH 54642 19980622
1999Austria► SubscribePRODUCT NAME: ''SILDENAFIL'' UND DESSEN PHARMAZEUTISCH ANNEHMBAREN SALZE, EINSCHLIESSLICH DES CITRATS; NAT. REGISTRATION NO/DATE: EU/1/98/077/001 - EU/1/98/077/012 19980914; FIRST REGISTRATION: LI 54642 01-54642 03 19980622
C0007Belgium► SubscribePRODUCT NAME: SILDENAFIL, NATL REGISTRATION NO/DATE: EU/1/98/077/001 19980914; FIRST REGISTRATION: CH 54642 19980622
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
UBS
Queensland Health
Moodys
Boehringer Ingelheim
Cantor Fitzgerald
Teva
Novartis
Argus Health
Citi

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot